.png&w=384&q=75)
Bazedoxifene and conjugated estrogens combination is used to treat moderate to severe hot flashes and other symptoms of menopause in women with a uterus (womb). This medicine is also used to prevent osteoporosis (thinning of the bones) after menopause.
This Tablet pairs conjugated estrogens with bazedoxifene. Conjugated estrogens and bazedoxifene function by binding to and activating estrogen receptors (ER) α and β, which vary in proportion from tissue to tissue. Conjugated estrogens are composed of multiple estrogens and are agonists of ER- α and β. Bazedoxifene is an estrogen agonist/antagonist that acts as an agonist in some estrogen-sensitive tissues and an antagonist in others (e.g., uterus). The pairing of conjugated estrogens with bazedoxifene produces a composite effect that is specific to each target tissue. The bazedoxifene component reduces the risk of endometrial hyperplasia that can occur with the conjugated estrogens component.
Take one tablet orally once daily
Some products that may interact with this drug include: aromatase inhibitors (such as anastrozole, exemestane, letrozole), other estrogen agonist/antagonists (such as ospemifene, raloxifene), fulvestrant, tamoxifen, tranexamic acid.
Stomach upset, nausea/vomiting, bloating, breast tenderness, headache, or weight changes may occur.
It must not be used in women who are or may become pregnant.
It should not be used by lactating women. It is not known whether this drug is excreted in human milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving conjugated estrogens. Estrogen administration has been shown to decrease the quantity and quality of the milk.
In case of overdosage, there is no specific antidote, and the treatment should be symptomatic. Symptoms of overdosage of estrogen-containing products in adults and children may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue; withdrawal bleeding may occur
It should be stored at 20°C to 25°C.